Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2012
09/11/2012US8263588 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
09/11/2012US8263567 A lipophilic anthracycline with a pharmaceutically acceptable carrier for topical administration to a body surface and which has a higher lipophilicity than doxorubicin; valrubicin applied to mucous membranes; psoriasis; side effect reduction; not doxorubicin, daunorubicin, epirubicin or idarubicin
09/11/2012US8263349 Antibody specific for a mammalian sphingosine kinase type 2 isoform protein and methods of use thereof
09/11/2012US8263326 Compounds and methods for modulating activation of NF-κB
09/11/2012US8263077 Cell growth inhibitors containing anti-glypican 3 antibody
09/11/2012US8263070 Using immunoglobulin specific to receptor for OX-2 membrane glycoprotein as diagnostic and therapeutic tool for treatment and prevention of asthma, infection, allergies, skin and cell proliferative disorders
09/11/2012US8263067 Comprises viral nucleotide sequences coding protein for treatment of tumors; gene therapy
09/11/2012US8263066 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
09/11/2012US8263044 Stilbene like compounds as novel HDAC inhibitors
09/11/2012US8262054 Furnace mount
09/11/2012CA2699908C Resveratrol-containing compositions for modulating gene product concentration or activity
09/11/2012CA2633526C Metal-polysaccharide conjugates: compositions and synthesis
09/11/2012CA2551640C Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
09/11/2012CA2508573C Novel coumarins, their carboxamide derivatives, preparation methods, compositions, and uses
09/11/2012CA2506296C Water-soluble anionic bacteriochlorophyll derivatives and their uses
09/11/2012CA2466851C Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
09/11/2012CA2448123C Taci-immunoglobulin fusion proteins
09/11/2012CA2326407C Retroviral vectors including modified envelope escort proteins
09/07/2012WO2012119129A1 Interrogatory cell-based assays and uses thereof
09/07/2012WO2012119077A1 Co -administration of eribulin and farletuzumab for the treatment of breast cancer
09/07/2012WO2012119046A2 Heterocyclic compounds for the inhibition of pask
09/07/2012WO2012119010A2 Materials for inhibiting aromatase and method of using the same to diagnose, treat and monitor breast cancer
09/07/2012WO2012118930A2 Stable colloidal gold nanoparticles with controllable surface modification and functionalization
09/07/2012WO2012118915A2 Compositions and methods for treatment of tamoxifen resistant breast cancer
09/07/2012WO2012118857A2 Immunologically modified carbon nanotubes for cancer treatment
09/07/2012WO2012118850A1 Serine/threonine kinase inhibitors
09/07/2012WO2012118813A2 Anti-il-6 receptor antibodies and methods of use
09/07/2012WO2012118812A2 Substituted 6,5-fused bicyclic heteroaryl compounds
09/07/2012WO2012118492A1 Heterocyclic sulfonamides as raf inhibitors
09/07/2012WO2012118353A2 Pharmaceutical composition containing an endocytic motif and protein transduction domains for preventing or treating cancer
09/07/2012WO2012118349A2 Differentiation and proliferation method for natural killer cells from cd14-positive monocytes
09/07/2012WO2012118237A1 Anti-cancer prodrug activated by radiation or ultraviolet therapy and use thereof
09/07/2012WO2012118154A1 Novel vitamin d receptor modulator with partial agonist activity
09/07/2012WO2012118124A1 Novel chemokine receptor antagonist
09/07/2012WO2012118068A1 Antineoplastic agent and manufacturing method and use therefor
09/07/2012WO2012118042A1 Medicinal agent for inhibiting metastasis of malignant tumor
09/07/2012WO2012117532A1 Cancer inhibiting agent, antibody production enhancing agent, and therapeutic agent for hepatitis
09/07/2012WO2012117396A1 Tyrphostin derivative in combination with cytotoxic compounds for treating cancer
09/07/2012WO2012117323A1 Therapeutic cancer vaccine
09/07/2012WO2012117257A1 Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
09/07/2012WO2012117246A1 Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
09/07/2012WO2012117224A1 Dipyridinium derivatives
09/07/2012WO2012117062A1 Piperidinyl benzoimidazole derivatives as mpges-1 inihibitors
09/07/2012WO2012117059A1 Pharmaceutically active disubstituted pyridine derivatives
09/07/2012WO2012116989A1 Substituted heteroaryl 2', 3', 7', 7a' - tetrahydrospiro-[pyrrole-3, 6' - pyrrolo [1, 2-c] imidazole] - 1', 2 (1h, 5'h) -diones as anticancer agents
09/07/2012WO2012116975A1 Method for administration of a gamma secretase inhibitor
09/07/2012WO2012116666A1 Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin e2, method of production thereof and use thereof
09/07/2012WO2012116644A1 Targeting anti-tumor compound and preparation method and use thereof
09/07/2012WO2012116636A1 Oncolytic adenovirus for target therapy of human tumor and use thereof
09/07/2012WO2012116595A1 Tumor necrosis factor-α humanized antibody
09/07/2012WO2012116577A1 Chlorogenic acid analogue, preparation process and use thereof
09/07/2012WO2012116432A1 Treatment of cancer with dopamine receptor antagonists
09/07/2012WO2012087889A3 Dna methylation inhibitors
09/07/2012WO2012085608A3 Use of trifluoro phthalimides for the treatment of cancerous diseases
09/07/2012WO2012064150A3 Composition comprising benproperine derivatives as active ingredients for preventing and treating angiogenesis-related diseases
09/07/2012WO2012023033A3 Mch-i restricted epitopes containing non-natural amino acid residues
09/07/2012WO2011089234A8 Aqueous solution comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
09/07/2012CA2828636A1 Dipyridinium derivatives
09/07/2012CA2828478A1 Serine/threonine kinase inhibitors
09/07/2012CA2828401A1 Therapeutic cancer vaccine
09/07/2012CA2828349A1 Heterocyclic compounds for the inhibition of pask
09/07/2012CA2828326A1 Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
09/07/2012CA2828296A1 Method for administration of a gamma secretase inhibitor
09/07/2012CA2827892A1 Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
09/07/2012CA2827799A1 Tumor necrosis factor-a humanized antibody
09/07/2012CA2827581A1 Anti-il-6 receptor antibodies and methods of use
09/07/2012CA2826459A1 Pharmaceutically active disubstituted pyridine derivatives
09/07/2012CA2820709A1 Substituted quinoline compounds and methods of use
09/06/2012US20120226039 N-Phenyl-2-pyrimidine-amine Derivatives
09/06/2012US20120225954 Methods and compositions for the classification of non-small cell lung carcinoma
09/06/2012US20120225934 Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treatment of cancer thereof
09/06/2012US20120225933 Regulated expression systems
09/06/2012US20120225928 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
09/06/2012US20120225925 Micro-RNA Biomarkers and Methods of Using Same
09/06/2012US20120225924 Single-monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery
09/06/2012US20120225912 Novel colchicine derivatives, methods and uses thereof
09/06/2012US20120225907 Benzamide compounds useful as histone deacetylase inhibitors
09/06/2012US20120225899 Compounds and Compositions as Protein Kinase Inhibitors
09/06/2012US20120225890 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease
09/06/2012US20120225889 Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders
09/06/2012US20120225883 Compounds for inflammation and immune-related uses
09/06/2012US20120225882 Selective hydroxamate based mmp inhibitors
09/06/2012US20120225880 Pyrazole compounds and thiazole compounds as protein kinases inhibitors
09/06/2012US20120225878 Compounds
09/06/2012US20120225875 Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
09/06/2012US20120225872 Methods of preparing and using quinazoline and quinoline derivatives
09/06/2012US20120225871 Small-molecule modulators of trp-p8 activity
09/06/2012US20120225870 Methods for treating cancer resistant to erbb therapeutics
09/06/2012US20120225867 Androgen receptor modulating compounds
09/06/2012US20120225863 Heterocyclic compounds for the inhibition of pask
09/06/2012US20120225862 Heteroaryl benzamides, compositions and methods of use
09/06/2012US20120225861 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling
09/06/2012US20120225860 Method for administration of a gamma secretase inhibitor
09/06/2012US20120225859 Pyrimidine derivatives used as pi-3 kinase inhibitors
09/06/2012US20120225855 Triazolopyridine jak inhibitor compounds and methods
09/06/2012US20120225851 Compositions and methods useful for treating diseases
09/06/2012US20120225849 2-Methoxyestradiol (2-ME2) Prodrug with Enhanced Bioavailability for Prophylaxis or Treatment of Cancerous or Non-Cancerous Condition
09/06/2012US20120225847 Squaric acid derivatives as inhibitors of the nicotinamide
09/06/2012US20120225846 Heterocyclic compounds for the inhibition of pask
09/06/2012US20120225844 Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors
1 ... 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 ... 2211